

## Advanced Control Choice Formulary™ July 2024 Updates

Removals	Add-Backs
4	3

## **Removals**

Drug Class	Removed Product(s)	Formulary Options
Cardiovascular, Antilipemics, Omega-3 Fatty Acids*	VASCEPA**	icosapent ethyl, omega-3 acid ethyl esters
Endocrine and Metabolic, Contraceptives*	NUVARING**	ethinyl estradiol-etonogestrel, ANNOVERA
Endocrine and Metabolic, Gaucher Disease*	VPRIV	CERDELGA, CEREZYME
Pain, Opioid Analgesics*	tramadol tablet 100mg <sup>†</sup>	tramadol (except tramadol tablet 100 mg), tramadol ext-rel tablet

## **Add-Backs**

Drug Class	Product(s) Added
Antineoplastic Agents, Kinase Inhibitors*	XALKORI ORAL PELLETS (non-preferred)
Cardiovascular, Antilipemics, Omega-3 Fatty Acids*	icosapent ethyl
Endocrine and Metabolic, Contraceptives*	EluRyng, EnilloRing, ethinyl estradiol-etonogestrel, Haloette

## **New to Market Updates**

Drug Class	Product(s) Added
Anti-Infectives, Antiretroviral Combination Agents	CABENUVA
Endocrine and Metabolic, Enzyme Replacements	ELFABRIO

<sup>\*</sup>Class has existing formulary exclusions \*\*Multi-source Brand Product †Tramadol 100mg will be moving from an NDC-specific exclusion to a drug-specific exclusion effective July 1, 2024. This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates. Information listed is current as of April 30, 2024 and subject to change.